Lexeo Therapeutics said FDA discussions left the agency open to an accelerated approval pathway for LX‑2006, its Friedreich’s ataxia cardiomyopathy gene therapy, if pooled interim data from ongoing Phase I/II studies support a surrogate endpoint. The company reported improvements in cardiac and neurologic measures in interim datasets and saw an immediate stock uptick on the regulatory tone. Analysts view FDA openness as another signal of regulatory flexibility for gene therapies when robust, well‑controlled surrogate markers are available. Lexeo is preparing combined submissions and additional data packages to pursue earlier market access under accelerated provisions.